Integrum (INTEG) Q3 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 25/26 earnings summary
5 Mar, 2026Executive summary
Net sales for Q3 2025/26 were SEK 20.2 million, down 14.8% year-over-year, but up 6.3% at constant currency, reflecting underlying market growth despite currency headwinds.
Operating loss for the quarter was SEK -9.5 million, with a net loss after tax of SEK -11.5 million; non-recurring reorganization costs impacted results.
A rights issue was completed and oversubscribed, raising SEK 42.7 million before expenses; a bridge loan of SEK 7 million was secured and repaid.
Organizational changes focused on commercial efficiency and cost control were implemented, with a 20% reduction in cost base compared to the previous quarter.
Financial highlights
Q3 net sales: SEK 20.2 million (SEK 23.7 million prior year); 9-month net sales: SEK 66.3 million (SEK 64.0 million prior year).
Q3 operating result: SEK -9.5 million (SEK -7.4 million prior year); 9-month operating result: SEK -33.0 million (SEK -30.7 million prior year).
Q3 EPS: SEK -0.47 (SEK -0.18 prior year); 9-month EPS: SEK -1.29 (SEK -1.13 prior year).
Gross margin for Q3: 66% (81% prior year), impacted by currency and higher US tariffs.
Cash flow for Q3: SEK 22.4 million (SEK -19.5 million prior year); 9-month cash flow: SEK -9.4 million (SEK -2.2 million prior year).
Cash and cash equivalents at period end: SEK 30.2 million; equity: SEK 182.5 million.
Outlook and guidance
Cost efficiency program fully implemented; full effect expected in FY 2026/27.
Focus on execution, growth, and profitability with a leaner, performance-driven organization.
Commercial acceleration in the US and increased activity in Rest of World markets anticipated.
Latest events from Integrum
- Sales fell 9.5% as losses widened, but US deals and capital raise support future growth.INTEG
Q1 24/2523 Jan 2026 - Focus on sales productivity, targeted launches, and operational discipline to drive recovery.INTEG
Investor Update20 Jan 2026 - Q2 sales fell 21% year-over-year, but sequential growth and new financing support recovery.INTEG
Q2 24/2512 Jan 2026 - Net sales rose 28.9% and US sales grew 41%, but gross margin fell due to tariffs.INTEG
Q1 25/268 Jan 2026 - Sales fell 21% year-over-year; U.S. focus, cost controls, and new funding drive growth.INTEG
Q3 24/2523 Dec 2025 - Q2 sales up 2.6%, US leads growth, SEK 42.6M rights issue, cost cuts target profitability.INTEG
Q2 25/2621 Nov 2025 - US-driven growth offsets overall sales decline as Integrum accelerates OPRA® commercialization.INTEG
Q4 24/255 Jun 2025